Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.06 USD | +2.38% | +1.25% | -2.55% |
Financials (USD)
Sales 2024 * | 31.42M | Sales 2025 * | 121M | Capitalization | 1.75B |
---|---|---|---|---|---|
Net income 2024 * | -314M | Net income 2025 * | -256M | EV / Sales 2024 * | 46.4 x |
Net cash position 2024 * | 291M | Net cash position 2025 * | 223M | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
-5.47
x | P/E ratio 2025 * |
-7.3
x | Employees | 184 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.15% |
Latest transcript on Syndax Pharmaceuticals, Inc.
1 day | +2.38% | ||
1 week | +1.25% | ||
Current month | -11.51% | ||
1 month | -1.77% | ||
3 months | +4.15% | ||
6 months | +66.22% | ||
Current year | -2.55% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 53 | 15-05-04 |
Peter Ordentlich
FOU | Founder | 55 | 05-10-10 |
Neil Gallagher
PSD | President | 60 | 23-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 17-03-28 |
Dennis Podlesak
CHM | Chairman | 66 | 08-11-30 |
Pierre Legault
BRD | Director/Board Member | 63 | 17-01-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.12% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 21.06 | +2.38% | 678,543 |
24-04-25 | 20.57 | -1.06% | 589,013 |
24-04-24 | 20.79 | -0.86% | 367,583 |
24-04-23 | 20.97 | +0.05% | 872,149 |
24-04-22 | 20.96 | +0.77% | 665,136 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.55% | 1.75B | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- SNDX Stock